Cyprus
Key Insights
- 1
No psychedelic therapy is approved in Cyprus; patient access is limited to standard medicine, with ketamine only available as a regulated anaesthetic or off-label treatment.
- 2
Blossom records just 1 trial in Cyprus, 0 active, with ketamine and placebo as the only compounds studied.
- 3
Cyprus has no psychedelic research footprint to date: 0 research organisations are listed, so the country’s sole signal is a single ketamine trial.
- 4
The near-term catalyst is regulatory, not scientific: Cyprus’s pharmaceutical authorities oversee clinical-trial licensing, but Blossom shows no active pipeline yet.
Reimbursed Care Access
Cyprus maintains a restrictive statutory regime for classical psychedelics (psilocybin, MDMA, DMT, mescaline, most tryptamines and phenethylamines) with no routine authorised medical use outside clinical research. Ketamine is used clinically (including in research) and esketamine (Spravato) is authorised across the EU — access and public reimbursement in Cyprus is limited and dependent on national formulary / HIO (GeSY) decisions or private-pay arrangements and specialised clinic availability.
Quick Indicators
Clinical Trials
Active and completed clinical trials investigating psychedelic-assisted therapies in Cyprus.